GENERAL COMMENTS
To the authors: This study reports the safety and effectiveness of NOACs compared to VKA in patients with NVAF. The study population consists of a relatively large administrative database of primary care practices in the UK. After propensity score matching more than 6000 patients were included in the analysis. In summary, the study shows similar risks of ischemic stroke/systemic embolism and major bleeding in patients prescribed NOACs compared to subjects prescribed VKA. There was a higher risk of gastrointestinal bleeding and a trend towards less intracranial bleeding associated with the use of NOACs compared to VKA.
The study raises several concerns that the authors should address: 1. The database consists of administrative data. It seems that it contains laboratory values as well. The authors should look at the database and report the time in therapeutic range (TTR) in patients taking VKA. Otherwise, explain why this relevant information is not reported. This information will shed light in terms of the quality of oral anticoagulation in patients taking VKA in the comparison/referent group.
2. The definition of chronic kidney disease should be stated clearly and explain the definition used in the present study. The authors only give a slight reference to the CKD definition mentioning they had used glomerular filtration rate (GFR) and other potential clinical characteristics that can be associated with renal disease. But, the authors should use established criteria as recommended by clinical societies or guidelines. 
Loo and colleagues provided the results of an observational study, using the data of CPRD and matching new users of NOACs and VKA using a complex and multidimensional propensity score and focusing on CKD. The manuscript is well written, however I have major concern: The subgroup of interest, CKD, it is not defined in terms of eGFR. It should be mandatory in this context to evaluate the different stages of CKD. I am also curious to know how many dialysis patients were included in the VKA and how many dialysed patients were found to match. Minor concerns/comments: -Did the author account for antiplatelet use over-time for outcome analysis adjustments (not only for baseline PMS selection) -Please provide the amount of exact and fuzzy matches.
All of that being said, the manuscript was generally well-written.
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1 Response to Dr. Freddy Del-Carpio (Reviewer #1):
1. The database consists of administrative data. It seems that it contains laboratory values as well. The authors should look at the database and report the time in therapeutic range (TTR) in patients taking VKA. Otherwise, explain why this relevant information is not reported. This information will shed light in terms of the quality of oral anticoagulation in patients taking VKA in the comparison/referent group.
Response: We agree with the reviewer that reporting the time in therapeutic range (TTR) would indeed be informative as to the quality of anticoagulation among patients treated with VKA. However, as suggested in one of our previous studies, INR and TTR values are neither frequently nor systematically recorded within the CPRD (Azoulay et al. BMC Cardiovascular Disorders, 2012) , and therefore we expect that the vast majority of VKA users in our cohort would not have this information recorded. Moreover, we would not have a similar measure to assess the quality of anticoagulation among patients treated with NOAC. The limitations section of the manuscript has been revised to briefly address this limitation (page 13-14).
2. The definition of chronic kidney disease should be stated clearly and explain the definition used in the present study. The authors only give a slight reference to the CKD definition mentioning they had used glomerular filtration rate (GFR) and other potential clinical characteristics that can be associated with renal disease. But, the authors should use established criteria as recommended by clinical societies or guidelines.
Response: As suggested, the manuscript has been revised to include a detailed description of the definition that was used for chronic kidney disease (page 7). This algorithm was developed adapted from guidance from the UK's National Institute for Health and Care Excellence (NICE clinical guideline CG182, 2014), which defines CKD as abnormalities of kidney function or structure for more than three months. We broadened the NICE definition to include patients with a mild reduction in kidney function (GFR/eGFR between 60 and 90 mL/min/1.73m2).
Patients were defined as having CKD if they had one of the following, in the year prior to their first OAC prescription: 1) a diagnosis for CKD; 2) a kidney transplantation; 3) at least two sessions of dialysis; 4) at least two values for glomerular filtration rate (GFR) or estimated GFR (eGFR) <90 mL/min/1.73m2 and recorded at least three months apart; 5) at least one session of dialysis and one value for GFR/eGFR <90 mL/min/1.73m2, recorded at least three months apart; 6) at least two diagnoses for renal impairments not specified as chronic or acute and recorded at least three months apart; or 7) at least one diagnosis for a renal impairment not specified as chronic or acute, and one session of dialysis or one value for GFR/eGFR <90mL/min/1.73m2, recorded at least three months apart.
3. To estimate the GFR the authors used the CKD-EPI formula. Please explain why this formula was used and how it compares with the more widely used creatinine clearance formula (Cockcroft-Gault) that not only is used to adjust dosing according to renal function in clinical practice, but also it was the only used and reported in the large randomized clinical trials of NOACs in patients with atrial fibrillation.
Response: We agree that the Cockcroft-Gault equation is commonly used to estimate GFR, and that this is the equation that was used in the large NOAC trials. However, we used the CKD-EPI equation because it is recommended in the UK, in accordance with the National Institute for Health and Care Excellence (NICE clinical guideline CG182, 2014). Furthermore, it has been suggested that the CKD-EPI equation produces more accurate estimates of GFR, as compared to both the Cockcroft-Gault and the MDRD equations (Michels et al. Clin J Am Soc Nephrol, 2010). The manuscript has been revised to mention this rationale (page 7).
4. Please report under statistical analyses if for the use of the Cox models the proportional hazard assumption was tested, how it was tested and if did not comply, how the authors dealt with it during analyses.
Response: The proportional hazards assumption was verified using two different methods. First, we plotted the log(-log(survival)) function versus the log(survival) function. Second, we evaluated trends in the hazard ratio over time using a Wald chi-square test. In both cases, there was no evidence of the proportional hazards assumption being violated. The manuscript has been revised to include a brief description of these tests (page 7).
5. "READ" codes are used several times throughout the manuscript. Even though this may be something familiar to UK practitioners, for other is unknown. Please define it in a few words.
Response: We agree that Read codes may not be familiar to readers outside of the UK. Briefly, the Read classification scheme is a hierarchical clinical coding system that is used to record demographic information and family medical history, in addition to medical diagnoses, procedures, and services. The manuscript has been revised to include a brief description of this classification system on page 5.
6. Citation to the figure and tables in the text show a "reference source not found", please address and correct.
Response: We thank the reviewer for noting these errors, which came up during the conversion from Word to PDF. The manuscript has been revised to remove these errors.
7. The definition of major bleeding is something of concern. Even thought the authors address this issue under discussion, it would be relevant to somehow compare the widely used ISTH definition in other studies and RCTs of NOACs, with the definition used by the authors. Ideally, the authors should consider getting a subgroup or small random sample of subjects apply the ISTH definition and the author's definition and see how they correlate. If this is not feasible due to the database restrictions, explain under limitations.
Response: In fact, our definition for major bleeding was adapted based on the ISTH definition, and we apologize for the lack of details in the previous version of the manuscript. Our definition included the following criteria which are similar to the ISTH definition: bleeding requiring hospitalization or transfusion, bleeding resulting in death, or bleeding in a critical area. However, we were not able to account for falls in hemoglobin, as stipulated by the ISTH, considering our data source. The Clinical Practice Research Datalink is a primary care database, and it is unlikely that hemoglobin levels would be systematically recorded by the general practitioner, precluding the ability to quantify changes.
Nevertheless, we do not expect that this omission would substantially affect our outcome classification, given our adherence to all other criteria required by the ISTH. The manuscript has been revised to provide more details on the definition that we used for major bleeding in our study (page 6). The limitations section of the manuscript has also been revised to address the fact that we were not able to include drops in hemoglobin levels in our definition, as stipulated by the ISTH (page 13).
Reviewer: 2 Response to Dr. Daniel Caldeira (Reviewer #2):
1. The subgroup of interest, CKD, it is not defined in terms of eGFR. It should be mandatory in this context to evaluate the different stages of CKD. I am also curious to know how many dialysis patients were included in the VKA and how many dialysed patients were found to match.
Response: eGFR values were used to define CKD in our analyses, and were calculated based on serum creatinine results using the CKD-EPI creatinine equation. The manuscript has been revised to include a detailed description of the CKD definition that we used (page 7), which was adapted from guidance from the UK's National Institute for Health and Care Excellence (NICE clinical guideline CG182, 2014).
Patients were identified as having CKD if they had one of the following in the one year prior to their first OAC prescription: 1) a diagnosis for CKD; 2) a kidney transplantation; 3) at least two sessions of dialysis; 4) at least two values for glomerular filtration rate (GFR) or estimated GFR (eGFR) <90 mL/min/1.73m2 and recorded at least three months apart; 5) at least one session of dialysis and one value for GFR/eGFR <90 mL/min/1.73m2, recorded at least three months apart; 6) at least two diagnoses for renal impairments not specified as chronic or acute and recorded at least three months apart; or 7) at least one diagnosis for a renal impairment not specified as chronic or acute, and one session of dialysis or one value for GFR/eGFR <90mL/min/1.73m2, recorded at least three months apart.
Response: We agree that it is important to evaluate the different stages of CKD. Therefore, we first explored the distribution of CKD severity within our matched-cohort, based on GFR and eGFR values. The distribution is presented below and reported in the revised version of the manuscript (Supplementary Data).
Distribution of the severity of CKD within our matched stroke cohort CKD Stage N (%) VKA (n=2596) N (%) NOAC (n=2596) 5 (end stage) 21 (0.81) 2 (0.08) 4 (severe) 92 (3.54) 52 (2.00)
